In short
Rilvegostomig is an innovative bispecific antibody being investigated in multiple clinical trials for the treatment of various cancers, particularly non-small cell lung cancer (NSCLC). This article examines the ongoing research into rilvegostomig's potential as an immunotherapy agent, either alone or in combination with other treatments, to improve outcomes for cancer patients.
At a glance
- Drug Name
- Rilvegostomig (AZD2936)
- Drug Type
- Bispecific antibody targeting TIGIT and PD-1
- Primary Indications
- Non-small cell lung cancer (NSCLC), Biliary tract cancer, Hepatocellular carcinoma, Gastric cancer
- Administration
- Intravenous (IV) infusion, typically every 3 weeks (Q3W)
- Key Clinical Trials
- ARTEMIDE-Lung02, ARTEMIDE-Lung03, TROPION-Lung10, TROPION-Lung12, DESTINY-Lung03
- Combination Therapies
- Chemotherapy (e.g., platinum-based), Other immunotherapies (e.g., Datopotamab Deruxtecan), Targeted therapies
- Primary Endpoints
- Overall survival (OS), Progression-free survival (PFS), Objective response rate (ORR)
- Secondary Endpoints
- Duration of response (DoR), Disease control rate (DCR), Quality of life measures, Pharmacokinetics, Immunogenicity
- Safety Monitoring
- Adverse events (AEs), Serious adverse events (SAEs), Dose-limiting toxicities (DLTs)
- Development Stage
- Phase II and Phase III clinical trials
What is Rilvegostomig?
Rilvegostomig, also known as AZD2936, is a new type of cancer drug currently being studied in clinical trials. It belongs to a class of medications called bispecific antibodies, which are designed to target two different proteins in the body at the same time. Specifically, rilvegostomig targets two proteins called TIGIT and PD-1, both of which play important roles in regulating the immune system's response to cancer cells.
How Does Rilvegostomig Work?
Rilvegostomig works by helping the body's immune system fight cancer more effectively. It does this by blocking two different "checkpoint" proteins (TIGIT and PD-1) that cancer cells sometimes use to evade detection by the immune system. By targeting both of these proteins at once, rilvegostomig may be able to enhance the immune system's ability to recognize and attack cancer cells.
What Conditions Does Rilvegostomig Treat?
Rilvegostomig is being studied for the treatment of several types of cancer, including:
- Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer
- Biliary tract cancer: This includes cancers of the bile ducts and gallbladder
- Hepatocellular carcinoma: This is the most common type of liver cancer
- Intrahepatic cholangiocarcinoma: A type of liver cancer that starts in the bile ducts inside the liver
Current Clinical Trials
Rilvegostomig is currently being tested in several large-scale clinical trials, including:
- ARTEMIDE-Lung03: This study is comparing rilvegostomig to another immunotherapy drug called pembrolizumab in patients with advanced non-squamous non-small cell lung cancer
- ARTEMIDE-Lung02: Similar to ARTEMIDE-Lung03, but focusing on patients with squamous non-small cell lung cancer
- ARTEMIDE-Biliary01: This trial is testing rilvegostomig as an additional treatment after surgery for biliary tract cancer
- TROPION-Lung12: This study is looking at rilvegostomig in combination with another drug called datopotamab deruxtecan for early-stage lung cancer
Potential Benefits of Rilvegostomig
While research is still ongoing, early studies suggest that rilvegostomig may offer several potential benefits:
- Improved survival: Many trials are looking at whether rilvegostomig can help patients live longer without their cancer getting worse (progression-free survival) or increase overall survival
- Better tumor response: Researchers are studying if rilvegostomig can shrink tumors more effectively than existing treatments
- Combination potential: Rilvegostomig is being tested both alone and in combination with other cancer treatments, which may lead to more effective therapies
- New option for hard-to-treat cancers: Some of the cancers being studied, like biliary tract cancer, currently have limited treatment options
Possible Side Effects
As with all medications, rilvegostomig may cause side effects. While the full safety profile is still being studied, some potential side effects may include:
- Fatigue
- Nausea
- Decreased appetite
- Immune-related side effects (due to its effects on the immune system)
It's important to note that the exact side effects and their frequency are still being determined through clinical trials.
Future Outlook
Rilvegostomig is still in the experimental stage and is not yet approved for general use. However, the ongoing clinical trials are providing valuable information about its effectiveness and safety. If the results from these studies are positive, rilvegostomig could become an important new option for treating various types of cancer in the future.
Patients interested in learning more about rilvegostomig should speak with their healthcare provider about the latest research and whether participating in a clinical trial might be appropriate for their individual situation.